Lido Advisors’s Lineage Cell Therapeutics LCTX Stock Holding History

Lido Advisors’s Portfolio LCTX Stock Details LCTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-10,000	Closed	-$9K	–	837
2020 Q3	$9K	Hold	10,000	–	–	﹤0.01%	632
2020 Q2	$9K	Hold	10,000	–	–	﹤0.01%	597
2020 Q1	$8K	Hold	10,000	–	–	﹤0.01%	582
2019 Q4	$9K	Hold	10,000	–	–	﹤0.01%	651
2019 Q3	$10K	Hold	10,000	–	–	﹤0.01%	571
2019 Q2	$11K	Buy	+10,000	New	+$11.5K	﹤0.01%	534

Other funds holding LCTX

Broadwood Capital New York $1.91B AUM 44.39% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Defender Capital Charlotte, North Carolina $319M AUM 12.55% 1-Year Est. Return

PGP

Prescott General Partners Boca Raton, Florida $1.96B AUM 58.65% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

ECM

ExodusPoint Capital Management New York $15.5B AUM 38.81% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $5.69B AUM 60.64% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Lido Advisors's LCTX Position: Q4 2020 in Review

Lido Advisors sold out of Lineage Cell Therapeutics (LCTX) in Q4 2020, closing a stake of 10,000 shares — an estimated $9K sold.

Lido Advisors first reported a position in LCTX in Q2 2019 and held it in 6 quarters. The position peaked at $11K in Q2 2019. 89 funds tracked by Wall St. Rank hold LCTX as of Q4 2020.

Lido Advisors reported no remaining Lineage Cell Therapeutics position as of Q4 2020 after selling out during the quarter.
Lido Advisors sold 10,000 Lineage Cell Therapeutics shares in Q4 2020, an estimated $9K.
Lido Advisors first reported a position in Lineage Cell Therapeutics in Q2 2019 and held it in 6 quarters.
Lido Advisors's Lineage Cell Therapeutics position peaked at $11K in Q2 2019.
89 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q4 2020.

Based on Lido Advisors's 13F filing for Q4 2020, filed 8 Feb 2021.